130 related articles for article (PubMed ID: 37872250)
1. Characteristics of incidental prostate cancer in the United States.
Scheipner L; Incesu RB; Morra S; Baudo A; Assad A; Jannello LMI; Siech C; de Angelis M; Barletta F; Tian Z; Saad F; Shariat SF; Briganti A; Chun FKH; Tilki D; Longo N; Carmignani L; De Cobelli O; Ahyai S; Karakiewicz PI
Prostate Cancer Prostatic Dis; 2023 Oct; ():. PubMed ID: 37872250
[TBL] [Abstract][Full Text] [Related]
2. Contemporary validation of cT1a vs. cT1b substaging of incidental prostate cancer.
Scheipner L; Baudo A; Jannello LMI; Siech C; de Angelis M; Tian Z; Saad F; Shariat SF; Briganti A; Chun FKH; Carmignani L; De Cobelli O; Mischinger J; Ahyai S; Karakiewicz PI
World J Urol; 2024 Apr; 42(1):269. PubMed ID: 38679642
[TBL] [Abstract][Full Text] [Related]
3. Effect on survival of local treatment in patients with low prostate-specific antigen, high Gleason score prostate cancer: a population-based propensity score-matched analysis.
Liu S; Wang XY; Huang TB; Niu Q; Yao K; Song X; Zhou SY; Chen Z; Zhou GC
Ann Palliat Med; 2020 Jul; 9(4):1708-1717. PubMed ID: 32527134
[TBL] [Abstract][Full Text] [Related]
4. Inverse stage migration patterns in North American patients undergoing local prostate cancer treatment: a contemporary population-based update in light of the 2012 USPSTF recommendations.
Leyh-Bannurah SR; Karakiewicz PI; Pompe RS; Preisser F; Zaffuto E; Dell'Oglio P; Briganti A; Nafez O; Fisch M; Steuber T; Graefen M; Budäus L
World J Urol; 2019 Mar; 37(3):469-479. PubMed ID: 29992380
[TBL] [Abstract][Full Text] [Related]
5. Assessing radiation dose for postoperative radiotherapy in prostate cancer: Real world data.
Hervás-Morón A; Domínguez-Rullán J; Santana VD; Valero M; Vallejo C; Sancho S; Fuentes JDG; López-Campos F; Gallego MC
World J Clin Oncol; 2022 Jul; 13(7):652-662. PubMed ID: 36157159
[TBL] [Abstract][Full Text] [Related]
6. Overall survival and cancer-specific survival were improved in local treatment of metastatic prostate cancer.
Miao Q; Wei Z; Liu C; Ye Y; Cheng G; Song Z; Chen K; Zhang Y; Chen J; Yue C; Ruan H; Zhang X
Front Oncol; 2023; 13():1130680. PubMed ID: 37207146
[TBL] [Abstract][Full Text] [Related]
7. Adverse upgrading and/or upstaging in contemporary low-risk prostate cancer patients.
Flammia RS; Hoeh B; Hohenhorst L; Sorce G; Chierigo F; Panunzio A; Tian Z; Saad F; Leonardo C; Briganti A; Antonelli A; Terrone C; Shariat SF; Anceschi U; Graefen M; Chun FKH; Montorsi F; Gallucci M; Karakiewicz PI
Int Urol Nephrol; 2022 Oct; 54(10):2521-2528. PubMed ID: 35838831
[TBL] [Abstract][Full Text] [Related]
8. Elderly patients aged ≥ 75 years with locally advanced prostate cancer may benefit from local treatment: a population-based propensity score-adjusted analysis.
Sheng W; Kirschner-Hermanns R; Zhang H
World J Urol; 2019 Feb; 37(2):317-325. PubMed ID: 29951790
[TBL] [Abstract][Full Text] [Related]
9. Radical prostatectomy in Denmark: Survival analysis and temporal trends in clinicopathological parameters with up to 20 years of follow-up.
Heering M; Berg KD; Brasso K; Iversen P; Røder MA
Surg Oncol; 2017 Mar; 26(1):21-27. PubMed ID: 28317581
[TBL] [Abstract][Full Text] [Related]
10. Marital status independently predicts prostate cancer survival in men who underwent radical prostatectomy: An analysis of 95,846 individuals.
Huang TB; Zhou GC; Dong CP; Wang LP; Luan Y; Ye JT; Gu X; Yao XD; Zheng JH; Ding XF
Oncol Lett; 2018 Apr; 15(4):4737-4744. PubMed ID: 29552113
[TBL] [Abstract][Full Text] [Related]
11. Local Therapy Improves Survival in Metastatic Prostate Cancer.
Leyh-Bannurah SR; Gazdovich S; Budäus L; Zaffuto E; Briganti A; Abdollah F; Montorsi F; Schiffmann J; Menon M; Shariat SF; Fisch M; Chun F; Steuber T; Huland H; Graefen M; Karakiewicz PI
Eur Urol; 2017 Jul; 72(1):118-124. PubMed ID: 28385454
[TBL] [Abstract][Full Text] [Related]
12. Survival outcomes of patients treated with local therapy for nonmetastatic prostate cancer with high prostate-specific antigen concentrations.
Ślusarczyk A; Baboudjian M; Zapała P; Yanagisawa T; Miszczyk M; Chlosta M; Krumpoeck P; Moschini M; Gandaglia G; Ploussard G; Rivas JG; Życzkowski M; Karakiewicz PI; Radziszewski P; Leapman MS; Shariat SF; Rajwa P
Prostate; 2023 Nov; 83(15):1504-1515. PubMed ID: 37545342
[TBL] [Abstract][Full Text] [Related]
13. Utility of Gleason pattern 4 morphologies detected on transrectal ultrasound (TRUS)-guided biopsies for prediction of upgrading or upstaging in Gleason score 3 + 4 = 7 prostate cancer.
Flood TA; Schieda N; Keefe DT; Breau RH; Morash C; Hogan K; Belanger EC; Mai KT; Robertson SJ
Virchows Arch; 2016 Sep; 469(3):313-9. PubMed ID: 27394432
[TBL] [Abstract][Full Text] [Related]
14. Recurrent Gleason Score 6 Prostate Cancer After Radiotherapy or Ablation: Should We Observe Them All? Results from a Large Multicenter Salvage Radical Prostatectomy Consortium.
Marra G; Calleris G; Conte F; Benfant N; Rajwa P; Ahmed M; Abreu A; Cacciamani G; Smith JA; Joniau S; Rodriguez-Sanchez L; Sanchez-Salas R; Cathcart P; Gill I; Karnes RJ; Tilki D; Shariat SF; Touijer K; Gontero P
Eur Urol Focus; 2023 Sep; ():. PubMed ID: 37704503
[TBL] [Abstract][Full Text] [Related]
15. Trend of Adverse Stage Migration in Patients Treated with Radical Prostatectomy for Localized Prostate Cancer.
Preisser F; Marchioni M; Nazzani S; Bandini M; Tian Z; Saad F; Pompe RS; Briganti A; Budäus L; Montorsi F; Huland H; Graefen M; Tilki D; Karakiewicz PI
Eur Urol Oncol; 2018 Jun; 1(2):160-168. PubMed ID: 31100241
[TBL] [Abstract][Full Text] [Related]
16. Contemporary Pathological Stage Distribution After Radical Prostatectomy in North American High-Risk Prostate Cancer Patients.
Chierigo F; Borghesi M; Würnschimmel C; Flammia RS; Sorce G; Hoeh B; Hohenhorst L; Tian Z; Saad F; Tilki D; Gallucci M; Briganti A; Montorsi F; Chun FKH; Shariat SF; Mantica G; Suardi N; Terrone C; Karakiewicz PI
Clin Genitourin Cancer; 2022 Oct; 20(5):e380-e389. PubMed ID: 35618597
[TBL] [Abstract][Full Text] [Related]
17. Radical prostatectomy represents an effective treatment in patients with specimen-confined high pathological Gleason score prostate cancer.
Lughezzani G; Gallina A; Larcher A; Briganti A; Capitanio U; Suardi N; Lista G; Abrate A; Sangalli MN; Buffi N; Cestari A; Guazzoni G; Rigatti P; Montorsi F
BJU Int; 2013 May; 111(5):723-30. PubMed ID: 22487441
[TBL] [Abstract][Full Text] [Related]
18. Adverse Disease Features in Gleason Score 3 + 4 "Favorable Intermediate-Risk" Prostate Cancer: Implications for Active Surveillance.
Morlacco A; Cheville JC; Rangel LJ; Gearman DJ; Karnes RJ
Eur Urol; 2017 Sep; 72(3):442-447. PubMed ID: 27574819
[TBL] [Abstract][Full Text] [Related]
19. Optimal PSA Threshold for Androgen-Deprivation Therapy in Patients with Prostate Cancer following Radical Prostatectomy and Adjuvant Radiation Therapy.
Ahn HK; Lee KS; Kim D; Rha KH; Hong SJ; Chung BH; Koo KC
Yonsei Med J; 2020 Aug; 61(8):652-659. PubMed ID: 32734728
[TBL] [Abstract][Full Text] [Related]
20. The therapeutic efficacy of radical prostatectomy and external beam radiation therapy in patients with different pathological patterns of prostate cancer.
Zhao J; Sun G; Zhao F; Chen J; Zhu S; Xu N; Liu H; Liang J; Hu X; Zhang X; Ni Y; Dai J; Wang Z; Shen P; Liu Z; Chen N; Liu J; Zeng H
Asian J Surg; 2023 Oct; 46(10):4178-4185. PubMed ID: 36376185
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
